Table 2. Disease characteristics.
| N 278 | |
|---|---|
| Inflammatory bowel disease | |
| Crohn’s disease, n (%) | 43 (15) |
| HBI | 2 ± 3 |
| Ulcerative Colitis, n (%) | 93 (32) |
| MS | 2 ± 2 |
| Rheumatological disorders | |
| Axial Arthritis | 9 (3) |
| ASDAS | 1.5 ± 0.9 |
| Peripheral Arthritis | 60 (20) |
| DAS-28 | 2.2 ± 1 |
| Systemic Sclerosis | 14 (5) |
| MSI | 3 ± 3 |
| Systemic Lupus Erythematosus | 10 (3) |
| SELENA-SLEDAI | 3.5 ± 5 |
| Vasculitis | 7 (2) |
| BVAS irmingham Vasculitis Activity Score | 1.2 ± 2.2 |
| Dermatological disorders | |
| Psoriasis | 27 (9) |
| PASI | 1.7 ± 1.8 |
| Atopic dermatitis | 15 (5) |
| EASI | 27 ± 1 |
| Disease duration (years) | 10 ± 8 |
| ESR (mm/h) | 14 ± 14 |
| RCP (mg/l) | 6 ± 11 |
| Active Disease n (%) | 80 (29) |
| Surgery, n (%) | 17 (6) |
| Medications, n (%) | |
| DMARDs | 51 (18) |
| FANS | 7 (2) |
| Mesalamine | 183 (64) |
| Steroids | 53 (19) |
| Biological | 95 (23) |
Note:
Continuous variables are shown as mean ± standard deviation, categorical variables are presented as number and proportion. Abbreviations: HBI, Harvey Bradshaw Index; MS, Mayo Score; ASDAS, Ankylosing Spondylitis Disease Activity Score; DAS-28, Disease Activity Score -28; MSI, Medsger Severity Index; SELENA-SLEDAI, Selena-Systemic Lupus Erythematosus Disease Activity Index; BVAS, Birmingham Vasculitis Activity Score; PASI, Psoriasis Activity Score Index; EASI, Eczema Area Severity Index; ESR, Erythrocyte Sedimentation Rate; RCP, Reactive C Protein; DMARDs, Disease modifying antirheumatic drugs.